Patents by Inventor Michael Higginbottom

Michael Higginbottom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CXCR4 Receptor Antagonists
    Publication number: 20220348577
    Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.
    Type: Application
    Filed: March 2, 2021
    Publication date: November 3, 2022
    Inventors: Giles Brown, Michael Higginbottom, Alison Stewart, Lee Patient, Allison Carley, Iain Simpson, Edward Daniel Savory, Kathryn Oliver, Andrew Graham Cole
  • Compounds I
    Patent number: 11040969
    Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 22, 2021
    Assignee: BENEVOLENTAI CAMBRIDGE LIMITED
    Inventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
  • CXCR4 receptor antagonists
    Patent number: 10995091
    Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: May 4, 2021
    Assignee: Proximagen LLC
    Inventors: Edward Daniel Savory, Alison Stewart, Allison Carley, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
  • Process for the preparation of (3S,4S)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3H-imidazo[4,5-C]pyridine-5(4H)-carboxylate
    Patent number: 10988473
    Abstract: The invention relates to an improved process for the synthesis of (3S, 4S)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3H-imidazo[4,5-c]pyridine-5(4H)-carboxylate, and pharmaceutically acceptable salts thereof, such as the methanesulphonic acid salt.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: April 27, 2021
    Assignee: BENEVOLENTAl CAMBRIDGE LIMITED
    Inventors: Viet-Anh Anne Horgan, Olof Haglund, Lee Patient, Edward Savory, Michael Higginbottom, Michael Ashwood
  • PROCESS FOR THE PREPARATION OF (3S,4S)-TETRAHYDROFURAN-3-YL 4-ISOPROPYL-6,7-DIHYDRO-3H-IMIDAZO[4,5-C]PYRIDINE-5(4H)-CARBOXYLATE
    Publication number: 20200062746
    Abstract: The invention relates to an improved process for the synthesis of (3S,4S)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3H-imidazo[4,5-c]pyridine-5(4H)-carboxylate, and pharmaceutically acceptable salts thereof, such as the methanesulphonic acid salt.
    Type: Application
    Filed: October 25, 2017
    Publication date: February 27, 2020
    Applicant: Benevolentai Cambridge Limited
    Inventors: Anne HORGAN, Olof HAGLUND, Lee PATIENT, Edward SAVORY, Michael HIGGINBOTTOM, Michael ASHWOOD
  • COMPOUNDS I
    Publication number: 20190359611
    Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.
    Type: Application
    Filed: July 17, 2019
    Publication date: November 28, 2019
    Applicant: BENEVOLENTAI CAMBRIDGE LIMITED
    Inventors: Edward SAVORY, Michael HIGGINBOTTOM, Kathryn OLIVER, Viet-Anh Anne HORGAN
  • Compounds I
    Patent number: 10399973
    Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: September 3, 2019
    Assignee: BENEVOLENTAI CAMBRIDGE LIMITED
    Inventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
  • Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (SSAO)
    Patent number: 10316034
    Abstract: The mesylate and sulphate salts of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate, and hydrates thereof, and their use in medicine.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: June 11, 2019
    Assignee: BENEVOLENTAI CAMBRIDGE LIMITED
    Inventors: Edward Savory, Michael Higginbottom
  • CXCR4 RECEPTOR ANTAGONISTS
    Publication number: 20190062333
    Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.
    Type: Application
    Filed: October 22, 2018
    Publication date: February 28, 2019
    Applicant: Proximagen, LLC
    Inventors: Edward Daniel SAVORY, Alison STEWART, Allison CARLEY, Giles BROWN, Iain SIMPSON, Kathryn OLIVER, Lee PATIENT, Michael HIGGINBOTTOM, Andrew Graham COLE
  • CXCR4 receptor antagonists
    Patent number: 10155761
    Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: December 18, 2018
    Assignee: PROXIMAGEN, LLC
    Inventors: Edward Daniel Savory, Alison Stewart, Allison Carley, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
  • NEW COMPOUNDS I
    Publication number: 20180118744
    Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.
    Type: Application
    Filed: December 29, 2017
    Publication date: May 3, 2018
    Applicant: PROXIMAGEN LIMITED
    Inventors: Edward SAVORY, Michael HIGGINBOTTOM, Kathryn OLIVER, Viet-Anh Anne HORGAN
  • PHARMACEUTICAL SALT FORMS OF AN INHIBITOR OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO)
    Publication number: 20180111928
    Abstract: The mesylate and sulphate salts of (3S)-Tetrahydrofuran-3-yl (4S)-4-isopropyl-,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate mesylate, and hydrates thereof, and their use in medicine.
    Type: Application
    Filed: April 22, 2016
    Publication date: April 26, 2018
    Applicant: PROXIMAGEN LIMITED
    Inventors: Edward SAVORY, Michael HIGGINBOTTOM
  • Compounds I
    Patent number: 9890160
    Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: February 13, 2018
    Assignee: PROXIMAGEN LIMITED
    Inventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
  • CXCR4 Receptor Antagonists
    Publication number: 20170226106
    Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.
    Type: Application
    Filed: April 26, 2017
    Publication date: August 10, 2017
    Inventors: Edward Daniel Savory, Alison Stewart, Allison Carley, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
  • NEW COMPOUNDS I
    Publication number: 20170044157
    Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Inventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
  • 4,5,6,7-tetrahyroimidazo[4,5-c]pyridine compounds
    Patent number: 9493457
    Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: November 15, 2016
    Assignee: Proximagen Limited
    Inventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
  • TONABERSAT PRODRUGS
    Publication number: 20160318891
    Abstract: The invention relates to pharmaceutically active compounds having improved pharmacokinetic properties and being useful for the treatment or prevention of a range of conditions including migraine, epilepsy, non-epileptic seizures, brain injury (including stroke, intracranial haemorrhage and trauma induced) or cardiovascular diseases including myocardial infarction, coronary revascularization or angina. The compounds of the invention form a novel group of related prodrugs of formula (II), where Ar is a 3-chloro-4-fluorophenyl ring, a 3-chlorophenyl ring or a 4-fluorophenyl ring; and R is a hydrolysable group comprising an amino group or an acidic group.
    Type: Application
    Filed: December 22, 2014
    Publication date: November 3, 2016
    Applicant: PROXIMAGEN LIMITED
    Inventors: Edward Savory, Martyn Pritchard, Michael Higginbottom, William John O'Neil
  • CXCR4 receptor antagonists
    Patent number: 9353086
    Abstract: Disclosed are compounds that are antagonists of the CXCR4 receptor.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: May 31, 2016
    Assignee: Proximagen Limited
    Inventors: Edward Daniel Savory, Alison Stewart, Allison Carley, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
  • CXCR4 Receptor Antagonists
    Publication number: 20160046606
    Abstract: The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.
    Type: Application
    Filed: September 14, 2015
    Publication date: February 18, 2016
    Inventors: Edward Daniel Savory, Alison Stewart, Allison Carley, Giles Brown, Iain Simpson, Kathryn Oliver, Lee Patient, Michael Higginbottom, Andrew Graham Cole
  • Inhibitor compounds of semicarbazide-sensitive amine oxidases
    Patent number: 9227967
    Abstract: Disclosed are compounds which inhibit SSAO enzyme activity. Also disclosed are pharmaceutical compositions comprising these compounds and the use of these compounds in the treatment or prevention of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases, immune disorders and the inhibition of tumor growth.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: January 5, 2016
    Assignee: Proximagen Limited
    Inventors: David Evans, Allison Carley, Alison Stewart, Michael Higginbottom, Edward Savory, Iain Simpson, Marianne Nilsson, Martin Haraldsson, Erik Nordling, Tobias Koolmeister